Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / OPT - EyePoint Stock: Retaining My 'Risky Buy' Call - Pivotal Data Due Early 2026

OPT - EyePoint Stock: Retaining My 'Risky Buy' Call - Pivotal Data Due Early 2026

Opthea Limited

2025-06-12 11:03:51 ET

Investment Overview

Back in January this year, I covered EyePoint Pharmaceuticals, Inc. ( EYPT ) in a note for Seeking Alpha , calling its stock a "risky buy" ahead of a key readout for its lead and only clinical stage drug candidate Duravyu - vorolanib intravitreal insert - in patients suffering from diabetic macular edema - a serious eye condition that can result in vision loss....

For further details see:

EyePoint Stock: Retaining My 'Risky Buy' Call - Pivotal Data Due Early 2026

Stock Information
Company Name: Opthea Limited
Stock Symbol: OPT
Market: NASDAQ
Website: opthea.com
Menu
OPT OPT Quote OPT Short OPT News OPT Articles OPT Message Board
Get OPT Alerts

News, Short Squeeze, Breakout and More Instantly...